硝氮烯类合成阿片类药物临床经验:一项队列研究
该研究在新南威尔士州前瞻性识别并分析确证了2018年6月至2025年3月间的27例硝氮烯类阿片暴露。暴露者以年轻男性为主,包括20例意外急性阿片中毒和7例急性戒断。最常见暴露途径为电子烟吸入,其他包括注射、口服和鼻吸。急性中毒典型表现为镇静和低通气,严重者因心脏骤停和/或低氧血症需气管插管。纳洛酮有效,中位肠外逆转剂量为400 μg(四分位距400至800 μg),16例中11例接受纳洛酮者中有45%需要重复给药。
要点
- 27例分析确证的硝氮烯暴露中,20例为意外急性阿片中毒,7例为急性戒断,主要见于年轻男性。
- 最常见暴露途径为电子烟吸入,其他包括注射、口服和鼻吸;8/21例(38%)已知意图的病例中硝氮烯被主动寻求。
- 急性中毒典型表现为镇静和低通气,严重者因心脏骤停和/或低氧血症需气管插管。
- 纳洛酮有效,中位肠外逆转剂量为400 μg(四分位距400至800 μg),接受纳洛酮的11/16例中45%需要重复给药。
- 标准肠外纳洛酮剂量通常有效,但需持续监测以发现再麻醉化。
适用人群与场景
- 澳大利亚新南威尔士州基于州综合监测项目前瞻性识别的、分析确证硝氮烯类阿片暴露的病例队列,暴露时间为2018年6月至2025年3月。
- 共27例分析确证暴露,包括20例意外急性阿片中毒和7例急性戒断,以年轻男性为主。
处置流程与药物剂量
- 纳洛酮用于逆转硝氮烯急性中毒,中位肠外逆转剂量为400 μg(四分位距400至800 μg),接受纳洛酮的11/16例中45%需要重复给药。
- 严重中毒表现为心脏骤停和/或低氧血症时需气管插管。
- 使用纳洛酮后需持续监测以发现再麻醉化。
红旗征与不能漏的情况
- 急性中毒典型表现为镇静和低通气,严重者可出现心脏骤停和/或低氧血症,需气管插管。
- 接受纳洛酮逆转后存在再麻醉化风险,需持续监测。
研究设计与关键结果
- 研究类型为队列研究(基于州综合监测项目的前瞻性识别病例),共27例分析确证硝氮烯类阿片暴露,暴露时间为2018年6月至2025年3月。
- 检测到的最常见硝氮烯类化合物为普罗托尼氮烯(protonitazene)、普罗托尼氮杂平(protonitazepyne,N-吡咯烷基-普罗托尼氮烯)和异托尼氮烯(isotonitazene)。
- 最常见暴露途径为电子烟吸入,其他暴露途径包括注射、口服和鼻吸;8/21例(38%)已知意图的病例中硝氮烯被主动寻求。
- 20例意外急性阿片中毒和7例急性戒断,主要见于年轻男性。
- 纳洛酮有效,中位肠外逆转剂量为400 μg(四分位距400至800 μg),接受纳洛酮的11/16例中45%需要重复给药。
证据类型、等级与局限
- 证据类型为病例系列(队列研究),基于州综合监测项目的前瞻性识别病例。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于疑似硝氮烯类阿片中毒,标准肠外纳洛酮剂量通常有效,但需持续监测以发现再麻醉化。
- 硝氮烯类阿片表现出新的消费模式,包括电子烟吸入暴露以及作为其他药物销售产品中的意外使用。
- 定期使用硝氮烯类阿片存在阿片戒断风险,为新的观察结果。
- 作者认为,通过主动药物监测、公众教育和社区获取纳洛酮来监测趋势,对于减轻硝氮烯类阿片带来的危害至关重要。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVES: Nitazenes are illicit novel opioid agonists, and data describing the clinical course, management, and outcome of nitazene opioid poisoning are limited. The aim of this study is to describe our clinical experiences with analytically confirmed nitazene opioid exposures.
METHODS: We extracted data on analytically confirmed nitazene opioid exposures in a cohort of prospectively identified cases in a state-based comprehensive surveillance program in New South Wales, Australia.
RESULTS: We identified 27 laboratory-confirmed nitazene opioid exposures from June 2018 to March 2025. We observed 20 unintentional acute opioid poisonings and 7 acute withdrawals in predominantly younger men. Protonitazene, protonitazepyne (N-pyrrolidino-protonitazene), and isotonitazene were the most detected nitazene opioid compounds. The most common route of exposure was vaping; other exposures included injection, ingestion, and nasal insufflation. Nitazene opioids were sought in 8/21 (38%) of cases where intent was known. Acute poisoning typically presented with sedation and hypoventilation, necessitating endotracheal intubation in severe cases due to cardiac arrest and/or hypoxemia. Naloxone was effective, with a median parenteral reversal dose of 400 μg (interquartile range 400 to 800 μg) and repeat dosing was given in 45% of the 11/16 cases receiving naloxone.
CONCLUSION: This case series highlights that standard parenteral naloxone doses are typically effective, but ongoing monitoring is necessary to detect renarcotization. Nitazene opioids display novel consumption patterns, including exposure by vaping and unintentional use in products sold as containing another drug. The risk of opioid withdrawal from regular nitazene opioid use is a novel observation. Monitoring trends through active drug surveillance, public education, and community access to naloxone are crucial to mitigate the harm posed by nitazene opioid opioids.
参考来源
- Roberts DM, Tisdell B, Sajeev MF, et al. Clinical Experiences With the Nitazene Class of Synthetic Opioids: A Cohort Study. Ann Emerg Med. 2025. PMID: 40810707. doi:10.1016/j.annemergmed.2025.06.619
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。